Marco Sereno

1.8k total citations
7 papers, 51 citations indexed

About

Marco Sereno is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Marco Sereno has authored 7 papers receiving a total of 51 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 2 papers in Molecular Biology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Marco Sereno's work include Lung Cancer Diagnosis and Treatment (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Radiomics and Machine Learning in Medical Imaging (1 paper). Marco Sereno is often cited by papers focused on Lung Cancer Diagnosis and Treatment (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Radiomics and Machine Learning in Medical Imaging (1 paper). Marco Sereno collaborates with scholars based in United Kingdom, Italy and Spain. Marco Sereno's co-authors include Claire Smith, Madhumita Das, John Le Quesne, Leah Officer-Jones, Alistair Hay, David A. Moore, Amy L. Byers, Catrin Pritchard, Apostolos Nakas and Ruth V. Spriggs and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cochrane Database of Systematic Reviews.

In The Last Decade

Marco Sereno

7 papers receiving 51 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marco Sereno United Kingdom 4 27 16 10 10 10 7 51
Núria Rabella García Spain 4 24 0.9× 10 0.6× 11 1.1× 7 0.7× 7 0.7× 6 68
M. Serra Mitjans Spain 5 52 1.9× 11 0.7× 24 2.4× 13 1.3× 2 0.2× 7 64
Claire Smith United Kingdom 5 28 1.0× 20 1.3× 10 1.0× 12 1.2× 5 63
Anna Polakiewicz-Gilowska Poland 4 18 0.7× 23 1.4× 28 2.8× 6 0.6× 2 0.2× 16 52
Anna Pous Spain 4 19 0.7× 5 0.3× 38 3.8× 10 1.0× 7 0.7× 7 61
Diana Newman United States 5 17 0.6× 5 0.3× 4 0.4× 31 3.1× 4 0.4× 6 58
P. Mackenzie Australia 5 9 0.3× 10 0.6× 10 1.0× 23 2.3× 2 0.2× 13 44
Danijela Štrbac Slovenia 5 39 1.4× 13 0.8× 6 0.6× 5 0.5× 12 50
Kitti Maas Germany 4 17 0.6× 11 0.7× 16 1.6× 6 0.6× 6 42
Balukrishna Sasidharan India 4 21 0.8× 9 0.6× 7 0.7× 10 1.0× 11 41

Countries citing papers authored by Marco Sereno

Since Specialization
Citations

This map shows the geographic impact of Marco Sereno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Sereno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Sereno more than expected).

Fields of papers citing papers by Marco Sereno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Sereno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Sereno. The network helps show where Marco Sereno may publish in the future.

Co-authorship network of co-authors of Marco Sereno

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Sereno. A scholar is included among the top collaborators of Marco Sereno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Sereno. Marco Sereno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Powley, Ian, Cathy Richards, Hussein Uraiby, et al.. (2025). A histomorphological atlas of resected mesothelioma discovered by self-supervised learning from 3446 whole-slide images. Nature Communications. 16(1). 8891–8891. 1 indexed citations
2.
Sereno, Marco, Claire Smith, Madhumita Das, et al.. (2020). Inclusion of multiple high‐risk histopathological criteria improves the prediction of adjuvant chemotherapy efficacy in lung adenocarcinoma. Histopathology. 78(6). 838–848. 14 indexed citations
3.
Moore, David A., Marco Sereno, Madhumita Das, et al.. (2019). In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth—a clinically relevant distinction. Modern Pathology. 32(8). 1095–1105. 8 indexed citations
4.
Das, Madhumita, Marco Sereno, Claire Smith, et al.. (2019). Reduced Protumorigenic Tumor-Associated Macrophages With Statin Use in Premalignant Human Lung Adenocarcinoma. JNCI Cancer Spectrum. 4(2). pkz101–pkz101. 13 indexed citations
5.
Hay, Alistair, et al.. (2015). Asenapine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. 2015(11). CD011458–CD011458. 11 indexed citations
6.
Pitzalis, Sabrina, Marco Sereno, Giorgia Committeri, et al.. (2012). The Human Homologue of Macaque Area V6A. Journal of Vision. 12(9). 420–420. 1 indexed citations
7.
Chiappori, Alberto, Marco Sereno, Dmitry I. Gabrilovich, et al.. (2007). Phase II trial of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) immunized with p53-transduced dendritic cells (p53-DC): Immune sensitization to chemotherapy (CT). Journal of Clinical Oncology. 25(18_suppl). 3012–3012. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026